Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Oct 18;91(8):1420-4.
doi: 10.1038/sj.bjc.6602162.

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

S Chan  1
Affiliations
Review

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

S Chan. Br J Cancer. .

Abstract

mTOR is a downstream mediator in the PI3K/Akt signalling pathway, which plays a critical role in regulating basic cellular functions. These include cell proliferation, survival, mobility and angiogenesis. Rapamycin and its analogues (CCI-779, RAD001 and AP23573) have specific antagonistic action on the function of mTOR. This leads to inhibition of the downstream signalling elements and results in the cell cycle arrest in the G1 phase. This group of drugs may have a place in Oncology for the treatment of cancers, which occur as a result of increased activity of the PI3 kinase/Akt/m-TOR pathway. The basic structure of the pathway was reviewed in this article, together with results of the clinical studies targeting mTOR for cancer therapy. This is an exciting area for development and poses many challenges to researchers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A diagram of the mTOR pathway.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abraham RT, Wiederrecht GJ (1996) Immunopharmacology of rapamycin. Annu Rev Immunol 14: 483–510 - PubMed
    1. Alexandre J, Raymond E, Depenbrock H (1999) CCI-779, a new rapamycin analog, has antitumour activity at doses inducing only mild cutaneous effects and mucositis: early results of an ongoing phase 1 study. Proceedings of the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics. Washington, DC, November 16–19
    1. Aronica SM, Katzellenbogen B (1991) Progestrogene receptor regulation in uterine cells: stimulation by oestrogen, cyclic adenosine 3,5-monophosphate, and insulin like growth factor I and suppression by antioestrogens and protein kinase inhibitors. Endocrinology 128: 2045–2052 - PubMed
    1. Atkin MB, Hidalgo M, Stadler W, Logan T, Dutcher JP, Hudes G, Park Y, Marshall B, Boni J, Dukart G (2002) A randomises phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Meeting Proceedings American Society of Clinical Oncology: vol 21: Poster Presentation Abst 36
    1. Barbet NC, Schneider U, Helliwell SB, Stansfield I, Tuite MF, Hall MN (1996) TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 7: 25–42 - PMC - PubMed